AbbVie (NYSE: ABBV), a $323 billion biopharma giant, is in a similar spot. While the company remains on solid footing, boasting a gross profit margin just north of 70%, it still faces some hurdles. For example, its aesthetics division remains under pressure due to broader economic challenges and heightened competition. Moreover, changes to prescription drug pricing rules could affect profitability.